TY - JOUR T1 - Transition Between Treatments: What We Need to Know JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.201331 SP - jrheum.201331 AU - Kirsten Minden AU - Jens Klotsche Y1 - 2021/04/15 UR - http://www.jrheum.org/content/early/2021/04/10/jrheum.201331.abstract N2 - Recent decades have seen the introduction of many new therapeutics into pediatric rheumatology practice, particularly biologic disease-modifying antirheumatic drugs (bDMARD). These advances are a result of the biotechnological revolution in the pharmaceutical industry, specific legislation for the development of pediatric medicines, and large international collaborative networks. ER -